Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

OCTRU, the Cardiff Clinical Trials Unit and Nottingham CTU have come together to lead the Explain Initiative.   Funded by the NIHR, the group are currently seeking the views of those approached to take part in trials, those that have taken part in trials, those who work in trials (at sites and centrally) to give their opinions on the development of some Explainer Animations that would then be made freely available across the UKCRC CTU Network in the first instance.


Please visit the initiatives website to find out more at:


Or to go directly to the survey:

Similar stories

OCTRU - delivering answers to important clinical questions

The Oxford Clinical Trials Research Unit (OCTRU) has received NIHR benchmarking results and offers excellent value for money according to the report

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.